Litcius/Paper detail

Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial

Kazunori Murai, Hiroshi Ureshino, Takashi Kumagai, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi, Toshihiro Fukushima, Chikashi Yoshida, Nobuhiko Uoshima, Toru Kiguchi, Masayuki Mita, Jun Aoki, Satoshi Kimura, Satoshi Kimura, Kaori Karimata, Kensuke Usuki, Joji Shimono, Yoshiaki Chinen, Junya Kuroda, Yasufumi Matsuda, Kensuke Nakao, Takaaki Ono, Katsumichi Fujimaki, Hirohiko Shibayama, Chisaki Mizumoto, Tomoharu Takeoka, Katsuhiro Io, Takeshi Kondo, Masatomo Miura, Yousuke Minami, Takayuki Ikezoe, Jun Imagawa, Ayako Takamori, Atsushi Kawaguchi, Junichi Sakamoto, Shinya Kimura, Shinya Kimura

2021The Lancet Haematology64 citationsDOI

Topics & Concepts

MedicineDasatinibAdverse effectInternal medicineClinical endpointPopulationChronic myeloid leukaemiaPhases of clinical researchImatinibMyeloid leukemiaClinical trialOncologyGastroenterologyEnvironmental healthChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia ResearchLung Cancer Treatments and Mutations
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial | Litcius